 | ||
| New Target: One Big Pharmaceutical Stock with Even Bigger Potential Zacks Member, I cannot emphasize this enough: The time to add legal marijuana investments to your portfolio is now. Legalization referendums made a clean sweep in the elections. 6 were approved in 5 states. Now 37 states plus D.C. allow medical marijuana and 17 plus D.C. have legalized recreational weed. Next month Mexico is poised to follow. This means there is almost unimaginable profit potential. With so many states and the rest of North America on board, there will be tremendous pressure for imminent federal legislation. That looks to be the real jackpot. Current companies could blast off. New companies will emerge. Global sales already jumped to $24.6 billion in 2020, and they're expected to skyrocket another 250%, reaching $86 billion by 2028.¹ Given current developments, this estimate may be conservative. Zacks' Marijuana Innovators portfolio is already taking advantage. It recently closed trades of +147.0% in Innovative Industrial Properties, +39.7% in Aurora Cannabis, and +94.5% in GrowGeneration in as little as 3 months. Right now we're still riding 2 giant gains of +240.8% and +152.2%.² The good news for you is that we bought those companies near their lows and, in my view, they still have a long way to run. Plus, I'm lining up strong U.S.-listed companies that could rival or surpass those gains. In fact, Monday morning at 11:05 am ET, I'll post a big pharmaceutical stock with a much bigger upside. I've been tracking this extraordinary company for quite a while and it has recently acquired a major cannabis pharma player. Get back to us now and you can be first in line to see it, and also immediately access live picks that are already on our recommendation board. There's no need to hesitate. It only costs $1 to follow these trades for a full 30 days without a cent of additional obligation. Important: To make profiting more convenient, we are limiting the number of investors who will share them. The portfolio has briefly re-opened but will close again to public entry midnight Sunday, June 6 - tonight. All the Best,
| ||
 | ||
| ¹ Grand View Research ² As of 6/2/2021. The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". https://www.zacks.com/terms_of_service. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through May 3, 2021. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance_disclosure for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
Post a Comment
Post a Comment